Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although statin therapy reduces cardiovascular risk, its relationship with the development of diabetes is controversial. The first study (West of Scotland Coronary Prevention Study [WOSCOPS]) that evaluated this association reported a small protective effect but used nonstandardized criteria for diabetes diagnosis. However, results from subsequent hypothesis-testing trials have been inconsistent. The aim of this meta-analysis is to evaluate the possible effect of statin therapy on incident diabetes. RESEARCH DESIGN AND METHODS: A systematic literature search for randomized statin trials that reported data on diabetes through February 2009 was conducted using specific search terms. In addition to the hypothesis-generating data from WOSCOPS, hypothesis-testing data were available from the Heart Protection Study (HPS), the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study, the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), and the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), together including 57,593 patients with mean follow-up of 3.9 years during which 2,082 incident diabetes cases accrued. Weighted averages were reported as risk ratios (RRs) with 95% CIs using a random-effects model. Statistical heterogeneity scores were assessed with the Q and I2 statistic. RESULTS: In the meta-analysis of the hypothesis-testing trials, we observed a small increase in diabetes risk (RR 1.13 [95% CI 1.03–1.23]) with no evidence of heterogeneity across trials. However, this estimate was attenuated and no longer significant when the hypothesis-generating trial WOSCOPS was included (1.06 [0.93–1.25]) and also resulted in significant heterogeneity (Q 11.8 [5 d.f.], P = 0.03, I2 = 57.7%). CONCLUSIONS: Although statin therapy greatly lowers vascular risk, including among those with and at risk for diabetes, the relationship of statin therapy to incident diabetes remains uncertain. Future statin trials should be designed to formally address this issue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (162,163), which may be limited to those with diabetes risk factors.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [162]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have reported a modestly increased risk of incident type 2 diabetes with statin use (156,157), which may be limited to those with diabetes risk factors and/or impaired glucose tolerance.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In primary prevention, however, among individuals with no previous cardiovascular events, its net benefit is more controversial (156,168).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk individuals with previous MI or stroke (secondary prevention) and is strongly recommended.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“In primary prevention, however, among patients with no previous cardiovascular events, its net bene fi t is more controversial (129,140).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [129]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“To assess heterogeneity across studies, we used the Cochran Q statistic based on the pooled RR by Mantel-Haenszel and measured inconsistency (I(2); the percentage of total variance across studies attributable to heterogeneity rather than chance) of treatment effects across trials (9).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“The summary RR and its 95% CI were estimated using the DerSimonian and Laird method for random effects (8).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“Subsequent statin trials did not confirm this protective effect, and in the recent JUPITER a small but significant increase in physician-reported diabetes was reported among statin users compared with those taking placebo, although in the absence of any effect on glucose levels (6).”
ResultSelf-citationSever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Self-citation(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · cited 1×
“A few studies have suggested that statin use may result in an increase in A1C levels (2,17), although these effects have been quite small.”
BackgroundRosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Freeman, D. J., Norrie, J., Sattar, N., Neely, R. D. G., Cobbe, S. M., Ford, I., Isles, C., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., et al. (2001) · Circulation · doi:10.1161/01.cir.103.3.357 · Cited by 844 · cited 1×
“(1) reported an inverse association between pravastatin use and diabetes incidence in the WOSCOPS (RR 0.”
Background
Research works printed but not linked: 1
- Sabatine, 2004, High-dose atorvastatin asssociated with worse glycemic control: A PROVE-IT TIMI 22 substudy (Abstract), Circulation, 110, S834
Cited by
Items 201–300 of 439
Chang, S., Wu, L., Lee, C., Kuo, C.-T., Liu, J., Wen, M., Chen, W.-J., See, L., & Yeh, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.121 · Cited by 23
Saito, I., Azuma, K., Kakikawa, T., Oshima, N., Hanson, M. E., & Tershakovec, A. M. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0036-z · Cited by 24
“%) increased risk for developing diabetes [4,19].”
Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention
Rochlani, Y. M., Kattoor, A. J., Pothineni, N. V. K., Palagiri, R. D. R., Romeo, F., & Mehta, J. L. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.06.054 · Cited by 28
Ma, T., Chang, M.-H., Tien, L., Liou, Y., & Jong, G. (2011) · Drugs & Aging · doi:10.2165/11597250-000000000-00000 · Cited by 24
Ayadurai, S., Hattingh, L., Tee, L. B. G., & Said, S. N. M. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5897452 · Cited by 26
Statins and type 2 diabetes: genetic studies on target
Frayling, T. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61639-1 · Cited by 24
Núñez-Cortés, J. M., Cases, A., Gimilio, J. F. A., Barrios, V., Fuster, V. P., Pedro‐Botet, J., Pintó, X., & Cumplido, A. S. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0197-9 · Cited by 26
“indicates that statins may increase the risk of type 2 diabetes mellitus [16, 17].”
BackgroundStatin users have an elevated risk of dysglycemia and new‐onset‐diabetes
Zigmont, V. A., Shoben, A. B., Lü, B., Kaye, G. L., Clinton, S. K., Harris, R. E., & Olivo‐Marston, S. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3189 · Cited by 27
Statins and Cognitive Function: an Updated Review
Chatterjee, S., Krishnamoorthy, P. M., Ranjan, P., Roy, A., Chakraborty, A., Sabharwal, M. S., Ro, R., Agarwal, V., Sardar, P., Danik, J. S., et al. (2015) · Current Cardiology Reports · doi:10.1007/s11886-014-0559-3 · Cited by 24
Self-citationDevelopment of Thiolated-Graphene Quantum Dots for Regulation of ROS in macrophages
Oh, B., & Lee, C. H. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2000-7 · Cited by 21
“various side effects, such as muscle problems, sexual dysfunction and increased onset of type-2 diabetes (3).”
BackgroundHormonal therapy for breast cancer and diabetes incidence among postmenopausal women
Santorelli, M. L., Hirshfield, K. M., Steinberg, M. B., Rhoads, G. G., Lin, Y., & Demissie, K. (2016) · Annals of Epidemiology · doi:10.1016/j.annepidem.2016.04.004 · Cited by 23
Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol
Karmaus, P. W. F., Shi, M. Y., Perl, S., Biancotto, A., Candia, J., Cheung, F., Kotliarov, Y., Young, N. S., & Fessler, M. B. (2019) · JCI Insight · doi:10.1172/jci.insight.131530 · Cited by 23
“LDL-C 106 (109, 94) 48 (46, 54) 45 (44, 50) –0.”
BackgroundStatins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms, and Clinical Implications
Guber, K., Pemmasani, G., Malik, A. H., Aronow, W. S., Yandrapalli, S., & Frishman, W. H. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000348 · Cited by 23
Diabetogenic effects of cardioprotective drugs
Bell, D. S. H., & Gonçalves, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14295 · Cited by 23
“tes was also increased with rosuvastatin and subsequent investigations confirmed that most statins were mildly diabetogenic.(2,3) While most other cardioprotective drugs have little effect on glycaemic control or new-onset diabetes, other drugs (renin-angioten-”
BackgroundKim, M. J., Song, H., Koh, Y., Lee, H., Park, H. E., Choi, S. H., Yoon, J. W., & Choi, S.-Y. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1181879 · Cited by 23
Li, H., Lin, H., Zhao, H.-Y., Yang, X., Cheng, Y., Shen, P., & Zhan, S. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s158850 · Cited by 23
“Rajpathak et al 4 have conducted a meta-analysis of statins compared with placebo and included 57,593 patients from 6 trials and found an increased risk for incident diabetes mellitus (relative risk: 1.13; 95% CI: 1.03–1.23).”
InfluentialChellamma, J., Jabbar, P. K., Soumya, S., Jayakumar, R. V., Das, D., Girivishnu, G., Gopi, A., Gomez, R., Sreenath, R., & Nair, A. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0046 · Cited by 26
Salsalate reduces atherosclerosis through AMPKβ1 in mice
Day, E. A., Ford, R. J., Smith, B. K., Houde, V. P., Stypa, S., Rehal, S., Lhoták, Š., Kemp, B. E., Trigatti, B. L., Werstuck, G. H., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101321 · Cited by 20
Lipid-lowering agents and new onset diabetes mellitus
Athyros, V. G., Τζιόμαλος, Κ., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.489553 · Cited by 21
“A recent meta-analysis [15] of six RCTs (including JUPITER), including a total of 57,593 patients and 2082 NODM cases (mean follow-up of 3.”
MethodLee, S., Lee, Y. J., Kim, J., An, J., Kim, K., Lee, H., Kong, H., Song, Y., & Kim, K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.101 · Cited by 20
Nakamura, A., Monma, Y., Kajitani, S., Kozu, K., Ikeda, S., Noda, K., Nakajima, S., Endo, H., Takahashi, T., & Nozaki, E. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.02.005 · Cited by 19
Ajmera, M., Shen, C., & Sambamoorthi, U. (2016) · Population Health Management · doi:10.1089/pop.2016.0047 · Cited by 19
“A meta-analysis performed with data from the WOSCOPS study has shown that statin use did not increase the risk of new-onset diabetes.(26) However, other studies have reported that statin use is associated with a greater risk of new-onset diabetes.”
Singh, H., authorship., T. A. H. C. E. T. T. W. A. S. F., Sikarwar, P., authorship., T. A. H. C. E. T. T. W. A. S. F., Khurana, S., & Sharma, J. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.96 · Cited by 24
“007) was observed with no evidence of heterogeneity.(16) However, this estimate was no longer significant once a hypothesis-generating trial was included (RR 1.”
ResultStatins may increase diabetes, but benefit still outweighs risk
Hoogwerf, B. J. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22069 · Cited by 29
“Simsek et al 2 4 reported that hemoglobin A1c values increased by 0.3% with both atorvastatin 80 mg/ day and rosuvastatin 40 mg/day over 18 weeks.”
BackgroundInfluentialDiabetogenic Effect of Statins: A Double-Edged Sword?
Yoon, J. S., & Lee, H. W. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.6.415 · Cited by 22
Kim, Y.-S., Han, Y.-E., Choi, E.-A., You, N.-Y., Lee, J., You, H., Kim, Y., Kim, J., & Kang, H. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.08.005 · Cited by 22
Kumar, V., Kumar, S. P. M., & Tiku, P. K. (2021) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-021-10261-5 · Cited by 19
Daido, H., Horikawa, Y., & Takeda, J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.048 · Cited by 18
Maki, K. C., Dicklin, M. R., & Baum, S. J. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.004 · Cited by 19
Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk?
Ma, Y., Culver, A. L., Rossouw, J. E., Olendzki, B. C., Merriam, P. A., Lian, B. Q., & Ockene, I. S. (2012) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944712468499 · Cited by 21
“Metaanalyses place the risk of diabetes at 9–13%, with higher incidence at higher statin doses/potency and with higher baseline risk for diabetes [Sattar et al. 2010; Preiss et al. 2011; Rajpathak et al. 2009].”
BackgroundEvaluation of colesevelam hydrochloride for the treatment of type 2 diabetes
Younk, L. M., & Davis, S. N. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.672973 · Cited by 19
“To date though, evidence for or against this association has only come from post hoc and meta-analyses [50-53], as diabetes onset has not been evaluated as a study end point.”
Florentin, M., Liberopoulos, E. N., Rizos, C. V., Kei, A. A., Liamis, G. L., Kostapanos, M. S., & Elisaf, M. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0103 · Cited by 19
Type-2 diabetes and coronary heart disease: common physiopathology, viewed from autoimmunity
Onat, A., Dönmez, İ., Karadeniz, Y., Çakır, H., & Kaya, A. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.910114 · Cited by 19
“Statin therapy, risk of diabetes & CHD It has become established in meta-analyses in the past few years that long-term use of statin medication may be associated with excess risk of Type 2 diabetes [89,90].”
BackgroundOnat, A., Can, G., Murat, S. N., Çiçek, G., Örnek, E., & Yüksel, H. (2013) · The Anatolian Journal of Cardiology · doi:10.5152/akd.2013.175 · Cited by 23
“Statin use, Lp (a) and cardiometabolic risk Usage of statin drugs has been reported in meta-analyses (32, 33) to increase the risk of incident diabetes (HR 1.”
BackgroundMutschlechner, D., Tscharre, M., Huber, K., & Gremmel, T. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad052 · Cited by 20
Statins and Nonadherence: Should We RELATE Better?
Turin, A., Pandit, J. A., & Stone, N. J. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415578170 · Cited by 19
Mohammadnia, N., Los, J., Opstal, T. S. J., Fiolet, A. T. L., Eikelboom, J. W., Mosterd, A., Nidorf, S. M., Budgeon, C. A., Tijssen, J. G. P., Thompson, P. L., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1244529 · Cited by 17
Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
Parson, H. K. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s8376 · Cited by 19
Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials
Rahal, A. J., El‐Mallah, A., Poushuju, R. J., & Itani, R. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.10.16078 · Cited by 18
Sehra, D., Sehra, S., & Sehra, S. T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1338269 · Cited by 19
Statin treatment and increased diabetes risk. Possible mechanisms
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2019) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2018.12.001 · Cited by 19
“…two subjects were randomized to 20 mg of rosuvastatin daily or placebo The treatment with rosuvastatin for almost 2 years was associated with a 44% 5---8 A relationship risk of NODM observed in individuals receiving statins and the presence of other comorbidities, mainly the well-known…”
Integrative High Dimensional Multiple Testing with Heterogeneity under Data Sharing Constraints
Liu, M., Yin, X., Cho, K., & Cai, T. (2020) · PubMed · doi:10.48550/arxiv.2004.00816 · Cited by 19
“ease (Swerdlow et al., 2015). While the benet of statin has been consistently observed, it is not without risk. There has been increasing evidence that statins increase the risk of type II diabetes (Rajpathak et al., 2009; Carter et al., 2013). Swerdlow et al. (2015) demonstrated via both meta analysis of clinical tri…”
BackgroundRautio, N., Jokelainen, J. J., Oksa, H. H., Saaristo, T., Peltonen, M., Vanhala, M. J., Puolijoki, H., Moilanen, L., Tuomilehto, J. O., Keinanen-Kiukaanniemi, S. M., et al. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001472 · Cited by 19
Statin Intake Is Associated With Decreased Insulin Sensitivity During Cardiac Surgery
Sato, H., Carvalho, G., Sato, T., Hatzakorzian, R., Lattermann, R., Codère-Maruyama, T., Matsukawa, T., & Schricker, T. (2012) · Diabetes Care · doi:10.2337/dc11-2251 · Cited by 15
“100,000 participants concluded that long-term statin intake increases the risk of new-onset diabetes (9,25).”
BackgroundMancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.032 · Cited by 24
Association of Statin Usage and the Development of Diabetes Mellitus after Acute Pancreatitis
Thiruvengadam, N. R., Schaubel, D. E., Forde, K. A., Lee, P., Saumoy, M., & Kochman, M. L. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.05.017 · Cited by 15
Schrom, J., Caraballo, P. J., Castro, M. R., & Simon, G. (2013) · Europe PMC (PubMed Central) · Cited by 18
Sasaki, J., Otonari, T., Uchida, Y., Ikeda, Y., Biro, S., & Kono, S. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13532 · Cited by 16
Statins: Rationale, Mode of Action, and Side Effects
Sultan, S., D'Souza, A., Zabetakis, I., Lordan, R., Τσούπρας, Α., Kavanagh, E. P., & Hynes, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00006-9 · Cited by 25
Weir, M. R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15764 · Cited by 18
“41,42 However, it is important to note that, although this risk is slight, the benefits associated with lipid-lowering therapy on cardiovascular events rates are so substantial that they far outweigh the risk of the development of incident diabetes, even for patients at the highest risk for…”
Guo, X., Wei, W., Liu, M., Cai, T., Wu, C., & Wang, J. (2022) · Journal of the American Statistical Association · doi:10.1080/01621459.2022.2157727 · Cited by 23
Lin, Z., Wang, C., Shen, L., Hsiao, F., & Wu, F. L. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.12.006 · Cited by 19
Lee, S., Sung, J. M., Cho, I., Kim, H. C., & Chang, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195459 · Cited by 21
Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis
Ricci, G., Ciccone, M. M., Giordano, P., & Cortese, F. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180706144824 · Cited by 15
Beneficial Effects of Rosuvastatin Treatment in Patients With Metabolic Syndrome
Bostan, C., Yıldız, A., Özkan, A. A., Uzunhasan, I., Kaya, A., & Yiğit, Z. (2014) · Angiology · doi:10.1177/0003319714522107 · Cited by 15
“9 years.(44) During this meta-analysis, 2082 incident diabetes cases were accrued.”
BackgroundÖzen, G., Dell’Aniello, S., Pedro, S., Michaud, K. D., & Suissa, S. (2022) · Arthritis Care & Research · doi:10.1002/acr.24866 · Cited by 13
Duvnjak, L. S., & Blaslov, K. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.012 · Cited by 14
“Emerging evidence, however, suggest that long-term statin treatment is associated with type 2 diabetes mellitus (T2DM) occurrence (9-12).”
BackgroundParida, S., Swain, T. R., Routray, S. N., & Maiti, R. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/23741.9427 · Cited by 16
Deshmukh, A. B., Bai, S., Aarthy, T., Kazi, R. S., Banarjee, R., Rathore, R., Vijayakumar, M. V., Thulasiram, H. V., Bhat, M. K., & Kulkarni, M. J. (2017) · Molecular BioSystems · doi:10.1039/c7mb00305f · Cited by 16
Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update
Zanetti, H. R., Roever, L., Gonçalves, A., & Resende, E. S. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0708-z · Cited by 13
Adverse effects of statin therapy and their treatment
Cheon, D. Y., & Jo, S. (2022) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2022.4.e4 · Cited by 18
Chianelli, M., Armellini, M., Carpentieri, M. S., Coccaro, C., Cuttica, C. M., Fusco, A., Marucci, S., Nelva, A., Nizzoli, M., Ponziani, M. C., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303282327240507184902 · Cited by 15
Prevención de la diabetes mellitus tipo 2
Soriguer, F., Rubio‐Martín, E., & Rojo‐Martínez, G. (2012) · Medicina Clínica · doi:10.1016/j.medcli.2012.03.015 · Cited by 19
Wang, J., Jiang, W., Zhong, Y., Lü, B., Shao, J., Jiang, S., & Gu, P. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000047 · Cited by 12
“To date, it remains questionable whether statin treatment has a detrimental or favorable effect on diabetes.(15,16) The current study found that xuezhikang, which contains various statins and other ingredients,(17) is able to maintain metabolic homeostasis.”
BackgroundImpact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats
Momtazi‐Borojeni, A. A., Jaafari, M. R., Abdollahi, E., Banach, M., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/4757170 · Cited by 15
Vehko, T., Sund, R., Arffman, M., Manderbacka, K., Ilanne‐Parikka, P., & Keskimäki, I. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003414 · Cited by 12
Pharmacovigilance Working Party (PhVWP)
Wharf, C., London, E., O’Malley, K., & Terrace, E. (2011) · Cited by 12
Statin therapy and new-onset diabetes: an attempt at recommendations
Banach, M., & Mikhailidis, D. P. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.16 · Cited by 12
Kim, D.-W., Kim, D.-H., Park, J., Choi, M., Kim, S., Kim, H., Seul, D.-E., Park, S.-G., Jung, J., Han, K., et al. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0427-9 · Cited by 16
Kamada, Y., Kiso, S., Yoshida, Y., Chatani, N., Kizu, T., Hamano, M., Egawa, M., Takemura, T., Ezaki, H., Furuta, K., et al. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01082.x · Cited by 13
Maki, K. C., Dicklin, M. R., & Baum, S. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.006 · Cited by 13
A users' guide to understanding therapeutic substitutions
Mills, E. J., Gardner, D. M., Thorlund, K., Briel, M., Bryan, S., Hutton, B., & Guyatt, G. H. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.09.008 · Cited by 12
Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia
Kei, A. A., Liberopoulos, E., & Elisaf, M. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i6.365 · Cited by 11
Kosmas, C. E., Sourlas, A., Bouza, K. V., DeJesus, E., Silverio, D., Montan, P. D., & Guzman, E. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.20 · Cited by 11
Dyslipidemia in Chronic Kidney Disease
Streja, E., & Streja, D. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch34 · Cited by 12
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
“156,157 However, extensive RCT evidence shows that their cardiovascular benefits far outweigh this small diabeto-genic risk, even in primary prevention.”
Lin, J., Chen, P.-S., Lin, H., Tsai, L., Lin, S., & Li, Y. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63076 · Cited by 12
The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
Wan, S., Ding, Y., Ji, X., & Meng, R. (2021) · Aging and Disease · doi:10.14336/ad.2021.0412 · Cited by 11
Han, J. H., Joung, K. H., Lee, J. C., Kim, O. S., Choung, S., Kim, J. M., Kang, Y. E., Yi, H., Lee, J. H., Ku, B. J., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0402 · Cited by 15
“Since side effects, such as hepatotoxicity, myopathy, and elevated serum glucose, are frequently associated with a high dose of statin or the use of a potent statin, combination therapy with ezetimibe can allow for lower dose of statin and similar reduction in the level of LDL-C [9].”
BackgroundKlug, E., Raal, F. J., Marais, A., Taskinen, M.-R., Dalby, A., Schamroth, C., Rapeport, N., Jankelow, D., Blom, D. J., Catsicas, R., et al. (2013) · South African Family Practice · doi:10.1080/20786204.2013.10874296 · Cited by 12
Balancing the cardiometabolic benefits and risks of statins
Watts, G. F., & Ooi, E. M. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61301-4 · Cited by 11
Gruzdeva, O. V., Учасова, Е. Г., Dyleva, Y. A., Евгеньевна, А. О., Каретникова, В. Н., Shilov, A. A., & Барбараш, О. Л. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s149463 · Cited by 10
“In recent years, there has been an increase in reports in the literature on cases of people taking statins who develop T2DM.(5,15,16) In one of the largest meta-analyses, which included 91,140 participants and 13 clinical trials, the authors concluded that statin therapy was accompanied by a significant increase in th…”
InfluentialHammad, M. A., Abdo, M. S., Mashaly, A. M., Sulaiman, S. A. S., Alghamdi, S., Mangi, A. A., & Noor, D. A. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.07.005 · Cited by 10
Baul, P. B., Deepak, A. D., Kakkar, M., & Modi, S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.020 · Cited by 11
C‐reactive protein and incident diabetes in patients with arterial disease
Verhagen, S. N., Wassink, A. M. J., van der Graaf, Y., Visseren, F. L. J., & SMART Study Group (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12142 · Cited by 10
Co‐medication of pravastatin and paroxetine—A categorical study
Li, A., Ravindran, P. P., Renukunta, S., & Denduluri, S. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.151 · Cited by 10
“Hence, studies on statins or pravastatin therapy association with risk of type 2 diabetes mellitus have not been particularly conclusive.(17) On the other hand, selective serotonin reuptake inhibitor (SSRI) drugs (specifically paroxetine) have been associated with hyperglycemia and diabetes in various investigations.”
BackgroundSathyapalan, T., Coady, A., Kilpatrick, E. S., & Atkin, S. L. (2017) · Endocrine Connections · doi:10.1530/ec-17-0217 · Cited by 11
Urbano, F., Pino, A. D., Scicali, R., Filippello, A., Mauro, S. D., Scamporrino, A., Marchisello, S., Rabuazzo, A. M., Purrello, F., & Piro, S. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0173 · Cited by 11
PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
Xiao, Y., Ba, Z., Pang, S., Liu, D., Wang, H., Liang, H., Wang, Y., & Yuan, J. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311380 · Cited by 12
“This update is based on well-designed clinical studies and epidemiological data, indicating a 9% non-negligible risk of statin-induced Type 2 diabetes (T2D) in patients who received statins [40–42].”
MethodStatin Use and Hyperglycemia: Do Statins Cause Diabetes?
Bredefeld, C., Choi, P., Cullen, T., Nicolich-Henkin, S., & Waters, L. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01266-8 · Cited by 11
“Rajpathak et al. [23 ] 2009 A small increase in incident diabetes was observed but attenuated with inclusion of the WOSCOPs trial that used non-standard diagnostic criteria for diabetes.”
La diabetogenicidad de las estatinas: ¿son todas iguales? Estado de la cuestión
Tarruella, J. R., Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.02.001 · Cited by 16
“21,22 metaa-nálisis de Sattar et al. (fig.”
Simvastatin attenuates the aberrant expression of angiogenic factors induced by glucose variability
Dworacka, M., Iskakova, S., Wesołowska, A., Zharmakhanova, G. M., Stelmaszyk, A., Frycz, B. A., Jagodziński, P. P., & Dworacki, G. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.023 · Cited by 10
Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases
Kostapanos, M. S., Rizos, C. V., & Elisaf, M. (2014) · Drug Safety · doi:10.1007/s40264-014-0169-4 · Cited by 9
“Meta-analyses of randomized placebo- and standard care-controlled trials showed that statins increased the risk of new-onset diabetes by 9–13 % [153, 154].”
MethodKang, D. O., Seo, H. S., Choi, B. G., Lee, E. M., Kim, J. P., Lee, S. K., Im, S. I., Na, J. O., Choi, C. U., Lim, H. E., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.164 · Cited by 10
“However, recent meta-analyses have reported that statin therapy can be associated with an increased risk of new-onset diabetes [18,19], and also in a dose-dependent manner [20].”
BackgroundStatin-Induced Diabetes: Will It Change Clinical Practice?
Belalcazar, L. M., Raghavan, V. A., & Ballantyne, C. M. (2009) · Diabetes Care · doi:10.2337/dc09-1277 · Cited by 11
“(7) bring together six randomized placebo-controlled trials to explore diabetes risk with statins using a meta-analytical approach.”
BackgroundResultInfluentialStatin treatment and increased diabetes risk. Possible mechanisms
Climent, E., Benaiges, D., & Pedro‐Botet, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.10.003 · Cited by 9
Increased risk of glucose intolerance and type 2 diabetes with statins
Byrne, C. D., & Wild, S. H. (2011) · BMJ · doi:10.1136/bmj.d5004 · Cited by 9
Agoons, D. D., Musani, S. K., Correa, A., Golden, S. H., Bertoni, A. G., & Echouffo-Tcheugui, J. B. (2022) · Diabetic Medicine · doi:10.1111/dme.14895 · Cited by 11
Kao, D. P., Martin, J. L., Aquilante, C. L., Shalowitz, E. L., Leyba, K. R., Kudron, E. L., Reusch, J. E. B., & Regensteiner, J. G. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004343 · Cited by 9
Pintó, X., & Formiga, F. (2012) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2012.05.005 · Cited by 10
Metadata
- Authors
- Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M.
- Affiliations
- Albert Einstein College of Medicine (US)
- Cleveland Clinic (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Rajpathak, Swapnil N.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-10-01
- Volume
- 32
- Issue
- 10
- Pages
- 1924-1929
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2752935
- OpenAlex
- W2121535401
- Cited by
- 439
- References
- 21
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 20 · 2023: 15 · 2022: 19 · 2021: 19 · 2020: 16 · 2019: 34 · 2018: 21 · 2017: 28 · 2016: 27 · 2015: 45 · 2014: 41 · 2013: 50 · 2012: 44
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (5P60DK2054, P60DK020541)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin therapy, type 2 diabetes, incident diabetes risk, WOSCOPS, Heart Protection Study, ASCOT trial, JUPITER trial, CORONA trial, cardiovascular risk
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Male, Risk Factors, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

